Literature DB >> 19951909

The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis.

Angelo Sangiovanni1, Matteo A Manini, Massimo Iavarone, Raffaella Romeo, Laura V Forzenigo, Mirella Fraquelli, Sara Massironi, Cristina Della Corte, Guido Ronchi, Maria Grazia Rumi, Piero Biondetti, Massimo Colombo.   

Abstract

BACKGROUND: Contrast-enhanced ultrasound (CE-US), contrast CT scan and gadolinium dynamic MRI are recommended for the characterisation of liver nodules detected during surveillance of patients with cirrhosis with US. AIM: To assess the sensitivity, specificity, diagnostic accuracy and economic impact of all possible sequential combinations of contrast imaging techniques in patients with cirrhosis with 1-2 cm liver nodules undergoing US surveillance. PATIENTS/
METHODS: 64 patients with 67 de novo liver nodules (55 with a size of 1-2 cm) were consecutively examined by CE-US, CT, MRI, and a fine-needle biopsy (FNB) as diagnostic standard. Undiagnosed nodules were re-biopsied; non-malignant nodules underwent enhanced imaging follow-up. The typical radiological feature of hepatocellular carcinoma (HCC) was arterial phase hypervascularisation followed by portal/venous phase washout.
RESULTS: HCC was diagnosed in 44 (66%) nodules (2, <1 cm; 34, 1-2 cm; 8, >2 cm). The sensitivity of CE-US, CT and MRI for 1-2 cm HCC was 26, 44 and 44%, with 100% specificity, the typical vascular pattern of HCC being identified in 22 (65%) by a single technique versus 12 (35%) by at least two techniques carried out at the same time point (p=0.028). Compared with the cheapest dual examination (CE-US+CT), the cheapest single technique of stepwise imaging diagnosis of HCC was equally expensive (euro 26 440 vs euro 28 667), but led to a 23% reduction of FNB procedures (p=0.031).
CONCLUSIONS: In patients with cirrhosis with a 1-2 cm nodule detected during surveillance, a single imaging technique showing a typical contrast pattern confidently permits the diagnosis of HCC, thereby reducing the need for FNB examinations.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19951909     DOI: 10.1136/gut.2009.187286

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  114 in total

1.  Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma.

Authors:  M Sherman; K Burak; J Maroun; P Metrakos; J J Knox; R P Myers; M Guindi; G Porter; J R Kachura; P Rasuli; S Gill; P Ghali; P Chaudhury; J Siddiqui; D Valenti; A Weiss; R Wong
Journal:  Curr Oncol       Date:  2011-10       Impact factor: 3.677

2.  Hepatobiliary quiz-5 (2013).

Authors:  Swastik Agrawal; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2013-03

3.  Differentiation of early hepatocellular carcinoma from benign hepatocellular nodules on gadoxetic acid-enhanced MRI.

Authors:  H Rhee; M-J Kim; M-S Park; K A Kim
Journal:  Br J Radiol       Date:  2012-05-02       Impact factor: 3.039

Review 4.  LI-RADS 2017: An update.

Authors:  Ania Z Kielar; Victoria Chernyak; Mustafa R Bashir; Richard K Do; Kathryn J Fowler; Donald G Mitchell; Milena Cerny; Khaled M Elsayes; Cynthia Santillan; Aya Kamaya; Yuko Kono; Claude B Sirlin; An Tang
Journal:  J Magn Reson Imaging       Date:  2018-04-06       Impact factor: 4.813

5.  Fractal analysis of contrast-enhanced CT images to predict survival of patients with hepatocellular carcinoma treated with sunitinib.

Authors:  Koichi Hayano; Hiroyuki Yoshida; Andrew X Zhu; Dushyant V Sahani
Journal:  Dig Dis Sci       Date:  2014-02-22       Impact factor: 3.199

6.  Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma.

Authors:  Vincenzo O Palmieri; Daniela Santovito; Giuseppe Marano; Francesco Minerva; Lara Ricci; Felicia D'Alitto; Giuseppe Angelelli; Giuseppe Palasciano
Journal:  Radiol Med       Date:  2015-01-20       Impact factor: 3.469

7.  Non-alcoholic fatty liver disease-associated hepatocellular carcinoma: effect of hepatic steatosis on major hepatocellular carcinoma features at MRI.

Authors:  Scott M Thompson; Ishan Garg; Eric C Ehman; Shannon P Sheedy; Candice A Bookwalter; Rickey E Carter; Lewis R Roberts; Sudhakar K Venkatesh
Journal:  Br J Radiol       Date:  2018-08-29       Impact factor: 3.039

8.  Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma.

Authors:  Jordi Rimola; Alejandro Forner; Víctor Sapena; Neus Llarch; Anna Darnell; Alba Díaz; Angeles García-Criado; Lluís Bianchi; Ramon Vilana; Álvaro Díaz-González; Carmen Ayuso; Jordi Bruix; María Reig
Journal:  Eur Radiol       Date:  2019-08-01       Impact factor: 5.315

9.  Diabetes Mellitus Heightens the Risk of Hepatocellular Carcinoma Except in Patients With Hepatitis C Cirrhosis.

Authors:  Ju Dong Yang; Hager Amed Mohamed; Jessica L Cvinar; Gregory J Gores; Lewis R Roberts; W Ray Kim
Journal:  Am J Gastroenterol       Date:  2016-08-16       Impact factor: 10.864

10.  Rate of observation and inter-observer agreement for LI-RADS major features at CT and MRI in 184 pathology proven hepatocellular carcinomas.

Authors:  Eric C Ehman; Spencer C Behr; Sarah E Umetsu; Nicholas Fidelman; Ben M Yeh; Linda D Ferrell; Thomas A Hope
Journal:  Abdom Radiol (NY)       Date:  2016-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.